Get 25% off your first order — code NEW2026 · Text us +1 272-529-4722

LegitScript approvedLicensed providersFree shipping, nationwideHIPAA compliant

Zavzpret - Invictus Pharmacy

All medications

Urgent Care

Zavzpret

Nasal spray CGRP receptor antagonist ("gepant") for the acute treatment of migraine with or without aura in adults.

Reviewed by:Dr. Steve Malen, PharmDDr. Steven Blikstein, PharmD

from$594.84 Up to 58% off

Strength

How would you like to get this medication?

Currently out of stock

We’re restocking — check back soon.

Choose a strength and quantity to continue.

Free shipping, 3–5 days HIPAA-compliant Licensed U.S. pharmacists

Zavzpret (zavegepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist, a class of migraine medications known as "gepants." It is delivered as a single-use intranasal spray and is used for the acute treatment of migraine attacks, with or without aura, in adults — it is not approved for migraine prevention. CGRP is a protein released during migraine attacks that promotes blood vessel dilation, neurogenic inflammation, and transmission of pain signals. By blocking the CGRP receptor, zavegepant interrupts this pathway and helps relieve migraine pain and associated symptoms such as nausea, light sensitivity, and sound sensitivity. Zavzpret is administered as one spray (10 mg) into one nostril at the onset of a migraine attack. Only one dose should be used within a 24-hour period; the safety of treating more than a limited number of migraine attacks per month has not been established, and patients should discuss frequency of use with their prescriber. The most common side effect is an altered or unpleasant sense of taste (dysgeusia), which occurs in roughly 1 in 5 patients. Other reported effects include nasal discomfort, nausea, and vomiting. Zavzpret is contraindicated in patients with a known hypersensitivity to zavegepant or any component of the formulation; hypersensitivity reactions, including dyspnea and rash, have been reported. Patients should tell their prescriber about all other CGRP-targeting medications they use, since combining multiple gepants or CGRP monoclonal antibodies is generally not recommended without medical guidance.

What to expect from the online consultation

Complete a health screening
A short questionnaire about your health history and current symptoms — takes about 2 minutes.
Provider reviews your answers
A licensed provider reviews your screening answers, typically within 24 hours.
Prescription fulfilled
If approved, your Rx is sent to Invictus Pharmacy and you're notified by text or email. Free nationwide shipping.

Drug facts

drug Type: CGRP receptor antagonist ("gepant")
brand Names: Zavzpret
dosage Forms: Nasal Spray
generic Name: Zavegepant
typical Dosage: One spray (10 mg) in one nostril at the onset of a migraine attack; limit to one dose per 24 hours. Not for use as a preventive treatment.
controlled Substance: Not a controlled substance

More treatments for Urgent Care

Azelastine/Fluticasone Nasal Spray

Prescription nasal spray combining an antihistamine and a corticosteroid, used twice daily to relieve symptoms of seasonal allergic rhinitis in patients 6 years and older.

Zavzpret Use and Safety Considerations

Zavzpret (zavegepant) is used only for treating a migraine attack that has already started — it is not a preventive medication and will not reduce how often migraines occur. Patients should use it as directed by their prescriber, spraying once into one nostril as soon as migraine symptoms begin, and should not use more than one dose in a 24-hour period. How it works: zavegepant blocks the CGRP receptor, interrupting one of the key pathways involved in migraine pain, and can also help relieve associated nausea and light or sound sensitivity. What to expect: the most common side effect is a temporary change in taste, often described as bitter or unpleasant, which affects roughly 1 in 5 patients but typically resolves on its own. Some patients also notice mild nasal discomfort, nausea, or vomiting after use. Safety considerations: Zavzpret should not be used by anyone with a known allergy to zavegepant or to any ingredient in the spray. Stop use and seek medical attention right away for signs of a serious allergic reaction, such as difficulty breathing, swelling of the face or throat, or a widespread rash. Patients using other CGRP-targeting migraine medications (other gepants, or injectable CGRP monoclonal antibodies such as erenumab or fremanezumab) should discuss this with their prescriber before starting Zavzpret, since the safety of combining these therapies has not been well established. Because Zavzpret has not been studied extensively in pregnancy, breastfeeding, or in children, patients in these groups should talk to their prescriber before use.